Dao Tian Fu
Keine laufenden Positionen mehr
Karriereverlauf von Dao Tian Fu
Ehemalige bekannte Positionen von Dao Tian Fu
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
REMEGEN CO., LTD. | President | 02.09.2019 | 12.05.2023 |
LIVZON PHARMACEUTICAL GROUP INC. | Director/Board Member | 30.06.2014 | 27.09.2019 |
Corporate Officer/Principal | 01.07.2014 | 27.09.2019 | |
Livzon MABPharm Inc.
Livzon MABPharm Inc. Pharmaceuticals: MajorHealth Technology Part of ZHU HAI Livzon Biologics Ltd., Livzon MABPharm Inc. researches, develops, and sells biopharmaceutical products and antibody drugs. The private company is based in Zhuhai, China. | Chief Executive Officer | 01.01.2012 | 01.09.2019 |
EPIRUS BIOPHARMACEUTICALS, INC. | Director/Board Member | 15.07.2014 | 25.07.2016 |
REVO BIOLOGICS INC | Corporate Officer/Principal | 01.01.1998 | 01.01.2001 |
Neose Pharmaceuticals, Inc. | Corporate Officer/Principal | 01.01.1992 | 01.01.1998 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | - | - |
LUNGLIFE AI, INC. | Director/Board Member | 01.05.2015 | - |
Zalicus, Inc.
Zalicus, Inc. Pharmaceuticals: MajorHealth Technology Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA. | Director/Board Member | 07.05.2014 | - |
Ausbildung von Dao Tian Fu
Iowa State University | Doctorate Degree |
Shandong University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 8 |
China | 5 |
Operativ
Director/Board Member | 4 |
Corporate Officer/Principal | 3 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 8 |
Consumer Services | 3 |
Health Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
LIVZON PHARMACEUTICAL GROUP INC. | Health Technology |
LUNGLIFE AI, INC. | Health Services |
EPIRUS BIOPHARMACEUTICALS, INC. | Health Technology |
REMEGEN CO., LTD. | Health Technology |
Private Unternehmen | 5 |
---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Neose Pharmaceuticals, Inc. | |
rEVO Biologics, Inc.
rEVO Biologics, Inc. BiotechnologyHealth Technology rEVO Biologics, Inc. engages in the development and commercialization of specialty therapeutics to address unmet medical needs in patients with rare, life-threatening conditions. Its products include ATryn, which prevents blood clots during and after surgery and childbirth for patients with hereditary antithrombin deficiency. The company was founded in February 1993 and is headquartered in Framingham, MA. | Health Technology |
Livzon MABPharm Inc.
Livzon MABPharm Inc. Pharmaceuticals: MajorHealth Technology Part of ZHU HAI Livzon Biologics Ltd., Livzon MABPharm Inc. researches, develops, and sells biopharmaceutical products and antibody drugs. The private company is based in Zhuhai, China. | Health Technology |
Zalicus, Inc.
Zalicus, Inc. Pharmaceuticals: MajorHealth Technology Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Dao Tian Fu
- Erfahrung